P.T., J.C. and E. S. Tai conceived the overall program strategy and provided overarching scientific and implementation leadership. E. S. Tai and E. S. Tan led clinical activities across phase II CIPs. M.L. led data curation and the development of the national genomic research resource enabling large-scale analyses and clinical translation. J.C., X.S., K.K.Y. and C.-Y.C. conceived the SG100K population study and led its delivery at their respective institutions. T.M. led the phenotypic data analysis, supported genotype–phenotype correlation studies across cohorts and contributed to manuscript writing. S.W.S. oversaw manuscript writing, program-wide operational planning, implementation coordination and national-level integration. J.N., K.R. and A.M. co-led the clinical translation and implementation of the Hereditary Cancer Clinical Implementation Pilot (CIP). T.S., S.P. and H.L.W. co-led the FHCARE CIP, while H.L.W., E.A.G.L. and B.C.G. co-led the Pharmacogenomics CIP. K.H.N. and D.M. co-led the RAPIDS CIP. Y.W., M. Hartman and J. Li co-led the BREATHE CIP. K.K.Y., W.T.H., C.-Y.C., C.S., X.S., J. Lee and S.W. led recruitment and clinical phenotyping as cohort principal investigators. C.G.Y.L. and J.Y. supported participant recruitment, phenotyping and follow-up activities. T.M., N.S., P.J. and X.W. analyzed phenotypic data and supported genotype–phenotype correlation and health informatics analyses. M. Hebrard, P.V.-G. and N.B. performed genomic and statistical data analyses. P.V.-G. and N.B. developed and implemented bioinformatics workflows and analytical pipelines. C.B., B.C.A.L. and C.C.K. oversaw DNA extraction and laboratory quality procedures. R.W. supported the clinical translation of the carrier screening program through the Diagnostics Development Hub (DxD Hub). Y.B., W.K.L. and S.J. contributed to variant curation and clinical interpretation and supported the return of genomic results and genetic counseling activities. M.S. and T.L. designed and conducted empirical research on the ethical and societal dimensions of precision medicine. K.S. contributed to the development of governance and data access policies. W.Z. contributed to the conceptualization and operationalization of the Pharma Pre-Competitive Consortium (PCC). P.Y.L. and M.K. contributed to the conceptualization and operationalization of TRUST. D.L. and C.I.P. contributed to the conceptualization and operationalization of the clinical implementation pilots. E.W. supported program administration, logistics and cross-team operational coordination. All authors reviewed, edited and approved the final manuscript.
